Nobligan Retard (Tramadol Hydrochloride)

Tramadol Hydrochloride, the active ingredient in Nobligan Retard, is an opioid analgesic presented as an oral tablet for oral use. It is indicated for the relief of moderate to severe pain in adult patients when other analgesics are insufficient.

GNH USA supplies Nobligan Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tramadol Hydrochloride is employed to manage pain across several clinical contexts. It acts centrally to reduce the perception of painful stimuli.

Postoperative pain: provides analgesia to reduce discomfort after surgical procedures. Chronic musculoskeletal pain: helps control persistent pain associated with conditions such as osteoarthritis or back pain. Cancer‑related pain: offers moderate analgesic relief for patients with tumor‑associated pain when stronger opioids are not required.

Tramadol Hydrochloride may cause a range of adverse reactions, from mild to severe. Awareness of these effects supports safe use.

Common Side Effects: - Nausea: feeling of queasiness or an urge to vomit. - Dizziness: light‑headed sensation, especially on standing. - Constipation: reduced bowel movements or hard stools. - Headache: mild to moderate cranial pain. - Somnolence: increased sleepiness or fatigue. - Dry mouth: reduced salivation leading to a parched feeling.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be life‑threatening. - Seizures: sudden uncontrolled electrical activity in the brain. - Serotonin syndrome: agitation, hyperthermia, and muscle rigidity when combined with serotonergic agents. - Anaphylaxis: severe allergic reaction with rash, swelling, and airway compromise. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting. - Dependence or addiction: potential for misuse with prolonged exposure.

Before prescribing Nobligan Retard, clinicians should consider several safety measures to minimize risk.

Assess renal function: adjust dosing in patients with severe renal impairment. Monitor for respiratory depression: especially in opioid‑naïve individuals or those with pulmonary disease. Avoid use with MAO inhibitors: concurrent therapy can precipitate hypertensive crises. Caution in patients with a history of seizures: tramadol may lower seizure threshold. Pregnancy and breastfeeding: use only if the therapeutic benefit justifies potential fetal or neonatal risk. Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Tramadol Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis and serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): heightened risk of serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, barbiturates): additive sedation and respiratory depression. - Alcohol: potentiates CNS depression and dizziness. - Strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine): may reduce tramadol activation and analgesic effect.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine, tamoxifen): altered metabolism may affect drug levels. - Anticoagulants (e.g., warfarin): possible increased bleeding tendency. - Antihypertensive agents: enhanced hypotensive effect. - Anticholinergic drugs: may exacerbate constipation and urinary retention.